Whole-body diffusion-weighted imaging with apparent diffusion coefficient mapping for treatment response assessment in patients with diffuse large B-cell lymphoma: Pilot study

Investigative Radiology

Volumn 46, Issue 5, 2011, Pages 341-349

  Lin, Chieh ^a,b,c   Itti, Emmanuel ^a,b,d   Luciani, Alain ^a,b,e   Zegai, Benhalima ^a   Lin, Shih Jui ^f   Kuhnowski, Frédérique ^a,b   Pigneur, Frédéric ^a   Gaillard, Isabelle ^a   Paone, Gaetano ^a,b   Meignan, Michel ^a,b,d   Haioun, Corinne ^a,b   Rahmouni, Alain ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CNRS   (France)

^e INSERM   (France)

^f STANFORD UNIVERSITY   (United States)

Author keywords

apparent diffusion coefficient mapping; diffuse large B cell lymphoma; fluorodeoxyglucose positron emission tomography computed tomography; treatment response; whole body diffusion weighted imaging

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE; VINDESINE;

ADULT; AGED; APPARENT DIFFUSION COEFFICIENT MAPPING; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG UPTAKE; FALSE POSITIVE RESULT; FEMALE; GATED IMAGING; HUMAN; LARGE CELL LYMPHOMA; LUNG METASTASIS; MALE; MESENTERY LYMPH NODE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; PARAAORTIC LYMPH NODE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SPLENOMEGALY; TREATMENT RESPONSE; TUMOR LOCALIZATION; WHOLE BODY MRI;

EID: 79954829586     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3182087b03     Document Type: Article

References (33)

1. Thoeny HC, De Keyzer F. Extracranial applications of diffusion-weighted magnetic resonance imaging. Eur Radiol. 2007;17:1385-1393. (Pubitemid 46767586)
2. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol-a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol. 2000;18:3025-3030. (Pubitemid 30644128)
3. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287-1295. (Pubitemid 38375363)
4. Cheson BD, Horning SJ, Coiffier B, et al. NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244.
5. Rahmouni A, Luciani A, Itti E. Quantitative CT analysis for assessing response in lymphoma (Cheson's criteria). Cancer Imaging. 2005;5(Spec No A):S102-S106.
6. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94:429-433. (Pubitemid 29323856)
7. Rahmouni A, Luciani A, Itti E. MRI and PET in monitoring response in lymphoma. Cancer Imaging. 2005;5(Spec No A):S106-S112.
8. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586. (Pubitemid 350002966)
9. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-578. (Pubitemid 350002965)
10. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376-1381. (Pubitemid 41129604)
11. Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514-1523. (Pubitemid 41222425)
12. Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. JNucl Med. 2007;48:1626-1632. (Pubitemid 47572710)
13. Rahmouni A, Tempany C, Jones R, et al. Lymphoma: monitoring tumor size and signal intensity with MR imaging. Radiology. 1993;188:445-451. (Pubitemid 23216269)
14. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. Am J Roentgenol. 2007;188:1622-1635. (Pubitemid 46866868)
15. Huang MQ, Pickup S, Nelson DS, et al. Monitoring response to chemotherapy of non-Hodgkin's lymphoma xenografts by T(2)-weighted and diffusion-weighted MRI. NMR Biomed. 2008;21:1021-1029.
16. Kwee TC, Quarles van Ufford HM, Beek FJ, et al. Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol. 2009;44: 683-690.
17. Kwee TC, Fijnheer R, Ludwig I, et al. Whole-body magnetic resonance imaging, including diffusion-weighted imaging, for diagnosing bone marrow involvement in malignant lymphoma. Br J Haematol. 2010;149:628-630.
18. Lin C, Luciani A, Itti E, et al. Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol. 2010;20:2027-2038.
19. Haioun C, Mounier N, Emile JF, et al. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol. 2009;20:1985-1992.
20. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242. (Pubitemid 34438862)
21. Mounier N, Gisselbrecht C, Fitoussi O, et al. Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor-risk DLBCL NHL patients treated with up-front consolidative autotransplantation: a GELA phase II trial (LNH 2003-3). J Clin Oncol. 2009;27(suppl 15). Abstract 8507.
22. Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527-533.
23. King AD, Ahuja AT, Yeung DK, et al. Malignant cervical lymphadenopathy: diagnostic accuracy of diffusion-weighted MR imaging. Radiology. 2007; 245:806-813. (Pubitemid 350127351)
24. Uto T, Takehara Y, Nakamura Y, et al. Higher sensitivity and specificity for diffusion-weighted imaging of malignant lung lesions without apparent diffusion coefficient quantification. Radiology. 2009;252:247-254.
25. Kato H, Kanematsu M, Tanaka O, et al. Head and neck squamous cell carcinoma: usefulness of diffusion-weighted MR imaging in the prediction of a neoadjuvant therapeutic effect. Eur Radiol. 2009;19:103-109.
26. Mikhaeel NG, Timothy AR, O'Doherty MJ, et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma. 2000;39:543-553. (Pubitemid 32162393)
27. Le Bihan DJ. Differentiation of benign versus pathologic compression fractures with diffusion-weighted MR imaging: a closer step toward the "holy grail" of tissue characterization? Radiology. 1998;207:305-307. (Pubitemid 28259040)
28. Galban CJ, Maderwald S, Uffmann K, et al. Diffusive sensitivity to muscle architecture: a magnetic resonance diffusion tensor imaging study of the human calf. Eur J Appl Physiol. 2004;93:253-262. (Pubitemid 39534628)
29. Galban CJ, Maderwald S, Uffmann K, et al. A diffusion tensor imaging analysis of gender differences in water diffusivity within human skeletal muscle. NMR Biomed. 2005;18:489-498. (Pubitemid 43013889)
30. Vandecaveye V, Dirix P, De Keyzer F, et al. Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma. Eur Radiol. 2010;20:1703-1714.
31. Juan CJ, Chang HC, Hsueh CJ, et al. Salivary glands: echo-planar versus PROPELLER Diffusion-weighted MR imaging for assessment of ADCs. Radiology. 2009;253:144-152.
32. Dale BM, Braithwaite AC, Boll DT, et al. Field strength and diffusion encoding technique affect the apparent diffusion coefficient measurements in diffusion-weighted imaging of the abdomen. Invest Radiol. 2010;45:104-108.
33. Takahara T, Kwee TC, Van Leeuwen MS, et al. Diffusion-weighted magnetic resonance imaging of the liver using tracking only navigator echo: feasibility study. Invest Radiol. 2010;45:57-63.